iBio, Inc. (IBIO)
Nasdaq · Healthcare · Biotechnology
$1.12−0.44%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $72.0M
- 52-week range
- $0.78 – $3.82
- 52-week change
- +29.89%
- EPS (trailing)
- −$0.32
- Analyst rating
- 1.1 Strong buy
Fiscal year to Jun 2026
- Revenue
- $100K (−75.00%)
- Net income
- −$32.8M
- Operating margin
- −35141.0%
- Diluted EPS
- −$0.32
- Free cash flow
- −$23.8M
From the company’s annual report on SEC EDGAR.
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Headquarters: San Diego, United States · 23 employees · ibioinc.com